## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.41 indicates fundamental undervaluation. Quality metrics strong (ROE 138%). Consistent execution (4/4 quarters beat estimates). Caution: declining volume (48% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($221.58)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. AbbVie stock slips today as Fed minutes loom in thin year-end trade**
- Source: ts2.tech | 20251230T125500 | Somewhat-Bearish | Relevance: 100%
- AbbVie shares fell approximately 0.8% in midday trading as investors awaited the Federal Reserve minutes during thin year-end liquidity. Traders are closely monitoring rate signals and the upcoming earnings window for direction, with rate expectations significantly influencing dividend payers like AbbVie. The company's decline left it trailing both the broader market and the defensive healthcare sector, as other major drugmakers also saw slight drops.

**2. Long-Term Stock Portfolio: 10 Best Stocks for the Next Decade**
- Source: Insider Monkey | 20251229T111100 | Bullish | Relevance: 100%
- This article, part of a larger series, highlights AbbVie Inc. (NYSE: ABBV) as a top stock for the next decade. Driven by strong immunology and neuroscience treatments, AbbVie reported significant revenue growth in Q3 2025, exceeding analyst estimates. The company's performance, bolstered by products like Skyrizi and Rinvoq, positions it well despite competitive pressures.

**3. AbbVie Inc. $ABBV Shares Sold by Sapient Capital LLC**
- Source: MarketBeat | 20251229T105817 | Somewhat-Bullish | Relevance: 100%
- Sapient Capital LLC reduced its stake in AbbVie Inc. (NYSE:ABBV) by 3.7% in Q3, selling 8,543 shares but still retaining 219,951 shares valued at approximately $49.11 million. Despite this sale, AbbVie remains Sapient's 23rd largest holding, comprising 0.8% of their portfolio. The article also notes other institutional investors have significantly increased their holdings in ABBV, and the company recently beat Q3 earnings estimates, issued strong Q4 2025 guidance, and raised its quarterly dividend.

**4. Meyer Handelman Co. Has $39.35 Million Stock Holdings in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251228T112056 | Bullish | Relevance: 100%
- Meyer Handelman Co. increased its stake in AbbVie Inc. by 3.1% during the third quarter, bringing its total holdings to 169,964 shares valued at $39.35 million, representing 1.2% of its portfolio. AbbVie surpassed Q3 earnings and revenue estimates and raised its quarterly dividend, while several other large institutional investors also made significant buys or sales of ABBV shares. The company's stock is trading up 0.1% with a market capitalization of $406.63 billion and analysts have a "Moderate Buy" consensus rating with a target price of $245.84.

**5. Carnegie Investment Counsel Purchases 25,146 Shares of AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251228T090828 | Bullish | Relevance: 100%
- Carnegie Investment Counsel increased its stake in AbbVie Inc. (NYSE:ABBV) by 22.0%, acquiring an additional 25,146 shares and now holding 139,194 shares valued at $32.23 million. This increase follows several analyst upgrades and price target lifts for AbbVie, contributing to a "Moderate Buy" consensus and a $245.84 target price. The company also reported strong Q3 EPS and raised its quarterly dividend, reflecting positive financial performance and investor confidence.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $269 | $261 | +3% |
| 2025-12-10 | HSBC | $265 | $225 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Overweight |
| 2025-12-10 | HSBC | up | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +1.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.41 indicates undervaluation relative to growth. Forward P/E 16.1x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $406.0B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.41 |
| Forward P/E | 16.1 |
| Current P/E | 21.6 |
| YoY Growth | 33.9% |
| EPS Direction | FALLING |

### Technicals

MRS_20 strengthening from 0.2% to 1.3% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.7pp (needs >4.0% for momentum thesis). MRS_5 at 0.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.62), confirming momentum. RSI neutral at 55. Volume at 48% of 20MA suggests lack of conviction. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.29% (CS: 71) | Neutral |
| RSI_14 | 55.0 | Neutral |
| MACD Histogram | 0.62 | Bullish |
| vs SMA20 | 1.014x | Above |
| vs SMA50 | 1.013x | Above |
| vs SMA200 | 1.115x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $229.74
- **Stop Loss:** $221.58 (3.6% risk)
- **Target:** $246.06 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 161
- **Position Value:** $36,988.14
- **Portfolio %:** 36.99%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*